Navigation Links
The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies

BURLINGTON, Mass., July 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, owing largely to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment. In 2023, these novel premium-priced agents—which include the anti-beta-amyloid monoclonal antibodies solanezumab (Eli Lilly) and gantenerumab (Roche), as well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn sales of $7 billion combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

Other key findings from the Pharmacor report entitled Alzheimer's Disease:

  • A new symptomatic alternative: Lundbeck/Otsuka's novel 5HT-6 receptor antagonist, Lu-AE58054, will launch as an adjunctive symptomatic treatment for AD and achieve blockbuster sales within the forecast period, capturing nearly 10 percent of major-market sales in 2023.
  • Population growth: The surging prevalence of AD as the population ages will drive growth across the major markets. We also expect diagnosis and drug-treatment rates to rise modestly in the pre-AD 1-2 years* and mild AD patient segments as DMTs and new diagnostic technologies gradually gain traction.
  • Current agents stay relevant: Today's clinical mainstays deliver modest symptomatic efficacy and do not affect disease progression but will remain the foundation of treatment throughout the forecast period—aided in part by growing generic availability. We forecast that acetylcholinesterase inhibitors (AChEIs) will continue to capture over 70 percent total patient share (across all AD subpopulations) in 2023, while NMDA receptor antagonist products, including Forest's Namenda/Namenda XR, will continue to capture approximately 35 percent patient share.

Comments from Decision Resources Group Analyst Alana Simorellis, Ph.D.:

  • "The projected launch of Eli Lilly's solanezumab, potentially the first ever DMT approved for the treatment of AD, will be a transformative event affecting the AD market as early as 2018. Commensurate with ongoing development and the views of experts in the field, we expect that future DMTs will most likely see the greatest uptake in the pre-AD and mild AD populations. Moreover, experts interviewed note that new symptomatic options also are sorely needed. Lundbeck/Otsuka's Lu-AE58054 and potentially others could partially address this need beginning in 2017."
  • "While AD drug development is understandably focused on disease modification, there exists an important area of additional unmet need for safer, more-effective symptomatic therapies that can control the behavior disturbances associated with later-stage AD. Development in this arena is underway, with clinical trials assessing promising agents like Lundbeck/Otsuka's brexpiprazole for AD-associated agitation."

*Decision Resources Group defines its proprietary pre-AD 1-2 years population as those patients who will go on to develop AD within the next one to two years.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo -


SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen Announces Positive Phase 3 Results for AMG 416 for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease Receiving Hemodialysis
2. FDA Grants Astellas Qualified Infectious Disease Product Designation for Isavuconazole for the Treatment of Invasive Candidiasis
3. New Study Shows Beta-Amyloid Imaging is Associated with Altered Diagnosis and Management of Alzheimers Disease
4. New Data Shows Cognitive Impairment Precedes and Predicts Subsequent Functional Impairment in Patients with Mild Alzheimers Disease
5. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
6. Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease
7. Pain Management Medical Journal Features BioElectronics Innovative Pain Products Because Pain is Not a Druggable Disease
8. Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimers Disease
9. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
10. Asleep During Brain Surgery: A Comfortable Alternative for Patients with Parkinsons Disease
11. Shield Therapeutics ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Post Your Comments:
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Finnleo, a ... Christmas Eve on several models of traditional and far-infrared saunas. , For ... Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European Grade ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... , ... On November 25, 2015, officials of Narconon Arrowhead , the ... of a new cutting edge recovery program that has been 50 years in the ... alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative behaviors ...
Breaking Medicine News(10 mins):